A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma

Background & aims: This phase Ib/II trial evaluated the safety and efficacy of capmatinib in combination with spartalizumab or spartalizumab alone in patients with advanced hepatocellular carcinoma (HCC). Methods: Eligible patients who had progressed or were intolerant to sorafenib received esca...

Descripció completa

Dades bibliogràfiques

Autors principals:	Armando Santoro, Eric Assenat, Thomas Yau, Jean-Pierre Delord, Michela Maur, Jennifer Knox, Stephane Cattan, Kyung-Hun Lee, Gianluca Del Conte, Christoph Springfeld, Elisa Leo, Alexandros Xyrafas, Lauren Fairchild, Feby Mardjuadi, Stephen L. Chan
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2024-04-01
Col·lecció:	JHEP Reports
Matèries:	Capmatinib Spartalizumab Hepatocellular carcinoma MET anti-programmed death-ligand 1
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2589555924000223
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!